Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Panicot, L.
Right arrow Articles by El Battari, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panicot, L.
Right arrow Articles by El Battari, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Glycobiology, Vol 9, 935-946, Copyright © 1999 by Oxford University Press

ORIGINAL ARTICLES

The formation of the oncofetal J28 glycotope involves core-2 beta6-N- acetylglucosaminyltransferase and alpha3/4-fucosyltransferase activities

L Panicot, E Mas, E Pasqualini, M Zerfaoui, D Lombardo, MO Sadoulet and A El Battari
INSERM U 260, Unite de Recherche de Physiopathologie des Regulations Hormono-Nutritionnelles, Faculte de Medecine-Timone, 27 Boulevard Jean Moulin, 13385 Marseilles-Cedex 5, France.

The feto-acinar pancreatic protein or FAPP, the oncofetal glycoisoform of bile salt-dependent lipase (BSDL), is characterized by the presence of the J28 glycotope recognized by mAbJ28. This fucosylated epitope is carried out by the O -linked glycans of the C-terminal mucin-like region of BSDL. This glycotope is expressed by human tumoral pancreatic tissues and by human pancreatic tumoral cell lines such as SOJ-6 and BxPC-3 cells. However, it is not expressed by the normal human pancreatic tissues and by MiaPaCa-2 and Panc-1 cells. Due to the presence of many putative sites for O -glycosylation on FAPP and BSDL, the structure of the J28 glycotope cannot be attained by classical physical methods. In the first part of the present study, we have determined which glycosyltransferases were differently expressed in pancreatic tumoral cell lines compared to normal tissues, focusing in part on fucosyltransferases (Fuc-T) and core-2 beta6-N- acetylglucosaminyltransferase (Core2GlcNAc-T). Our data suggested that alpha2-Fuc-T activity was decreased in the four cell lines tested (SOJ- 6, BxPC-3, MiaPaCa-2, and Panc-1). The alpha(1-3) and alpha(1-4) fucosylations were decreased in tumor cells that do not express the J28 glycotope whereas alpha4-Fuc-T and Core2GlcNAc-T activities were significantly increased in SOJ-6 cells which best expressed the J28 glycotope. Therefore, we wished to gain information about glycosyltransferases involved in the building of this structure by transfecting the cDNA encoding the mucin-like region of BSDL in CHO-K1 also expressing Core2GlcNAc-T and/or FUT3 and/or FUT7 activities. These CHO-K1 cells have been previously transfected with the cDNA encoding Core2GlcNAc-T and/or FUT3 and/or FUT7. Data indicated that the C- terminal peptide of BSDL (Cter) produced by those cells did not carry out the J28 glycotope unless Core2GlcNAc-T activity is present. Further transfection with FUT3 cDNA, increased the antibody recognition. Nevertheless, transfection with FUT3 or FUT7 alone did not generate the formation of the J28 glycotope on the C-terminal peptide. Furthermore, the Cter peptide produced by CHO-K1 cells expressing Core2GlcNAc-T was more reactive to the mAbJ28 after in vitro fucosylation with the recombinant soluble form of FUT3. These data suggested that the J28 glycotope encompasses structures initiated by Core2GlcNAc-T and further fucosylated by alpha3/4-Fuc-T such as FUT3, likely on GlcNAc residues.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. Benkoel, J.-P. Bernard, M.-J. Payan-Defais, L. Crescence, C. Franceschi, M. Delmas, M. Ouaissi, B. Sastre, J. Sahel, A.-M. Benoliel, et al.
Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues
Mol. Cancer Ther., February 1, 2009; 8(2): 282 - 291.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
M.-O. Sadoulet, C. Franceschi, M. Aubert, F. Silvy, J.-P. Bernard, D. Lombardo, and E. Mas
Glycoengineering of {alpha}Gal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope
Glycobiology, June 1, 2007; 17(6): 620 - 630.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Walcheck, A. Leppanen, R. D. Cummings, R. N. Knibbs, L. M. Stoolman, S. R. Alexander, P. E. Mattila, and R. P. McEver
The monoclonal antibody CHO-131 binds to a core 2 O-glycan terminated with sialyl-Lewis x, which is a functional glycan ligand for P-selectin
Blood, May 13, 2002; 99(11): 4063 - 4069.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Verine, J. Le Petit-Thevenin, L. Panicot-Dubois, A. Valette, and D. Lombardo
Phosphorylation of the Oncofetal Variant of the Human Bile Salt-dependent Lipase. IDENTIFICATION OF PHOSPHORYLATION SITE AND RELATION WITH SECRETION PROCESS
J. Biol. Chem., April 6, 2001; 276(15): 12356 - 12361.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.